Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.06% | -11.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.06% | -11.87% | |||
| Cost of Revenue | 15.13% | -22.29% | |||
| Gross Profit | -19.13% | -1.51% | |||
| SG&A Expenses | 10.05% | 0.92% | |||
| Depreciation & Amortization | -8.01% | 3.57% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.74% | -3.16% | |||
| Operating Income | -24.61% | -10.38% | |||
| Income Before Tax | -35.74% | -16.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.74% | -16.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.74% | -16.92% | |||
| EBIT | -24.61% | -10.38% | |||
| EBITDA | -28.45% | -11.55% | |||
| EPS Basic | 15.07% | -87.18% | |||
| Normalized Basic EPS | 15.22% | -91.67% | |||
| EPS Diluted | 15.07% | -87.18% | |||
| Normalized Diluted EPS | 15.22% | -91.67% | |||
| Average Basic Shares Outstanding | 59.51% | -37.17% | |||
| Average Diluted Shares Outstanding | 59.51% | -37.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||